Registered title, quoted from ClinicalTrials.gov
Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia
An open trial on B-cell acute lymphoblastic leukaemia, registered on ClinicalTrials.gov. Led by First Affiliated Hospital, Zhejiang University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06793241, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
3. Patients diagnosed with B-cell acute lymphoblastic leukemia by histological or immunotyping;
Inclusion criterion 3
4. Less than 100 days after receiving allogeneic hematopoietic stem cell transplantation;
Exclusion criterion 4
9. Patients who received anti-cancer chemotherapy or other drugs within 2 weeks prior to screening;
Exclusion criterion 9
10. ECOG score 0-2;
Inclusion criterion 14
6. Total bilirubin ≤51 ( μmol/L), alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal, creatinine ≤176.8 (μmol/L);
Inclusion criterion 10
7. Absolute neutrophil count: ≥ 0.5×109/L; Platelet: ≥ 30×109/L; Hemoglobin ≧60g/L;
Inclusion criterion 11
5. Hiv-infected person;
Exclusion criterion 5
6. Persons with active hepatitis B or C virus; Those who are not cured have active infections;
Exclusion criterion 6
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; scans and measurable lesions; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06793241, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- 1. Age ≥18 years old, gender unlimited;
- 2. Abnormal B cell immunotyping was CD19 positive;
- 3. Patients diagnosed with B-cell acute lymphoblastic leukemia by histological or immunotyping;
- 4. Meets the diagnosis of relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and includes any of the following conditions:
- No CR was obtained after standard chemotherapy;
- CR was induced for the first time, but the duration of CR was less than 12 months;
- R/R B-ALL that does not work after the first or more remedial treatments;
- Two or more relapses;
- 5. The researchers believed that the patient had been adequately treated, such as auto-HSCT, auto-CART could not be prepared or preparation failed. Autologous CAR-T preparation failure was defined as including too few autologous lymphocytes (<1×109) or insufficient expansion during preparation or failure to meet the release criteria;
- 6. Total bilirubin ≤51 ( μmol/L), alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal, creatinine ≤176.8 (μmol/L);
- 7. Absolute neutrophil count: ≥ 0.5×109/L; Platelet: ≥ 30×109/L; Hemoglobin ≧60g/L;
- 8. Echocardiography showed left ventricular ejection fraction (LVEF) ≥40%;
- 9. The estimated survival is more than 3 months;
- 10. ECOG score 0-2;
- 11. Women and men who are fertile must consent to the use of appropriate contraception before entering the study, during study participation, and for 6 months after transfusion (the safety of this therapy for the unborn child is not known, with unknown risks);
- 12. Subjects who are willing to participate in the study are able to understand and have the ability to sign informed consent.
Exclusion Criteria:
- 1. Known allergies to research preconditioning measures, etc;
- 2. People with a history of epilepsy or other central nervous system disorders;
- 3. People with a history of prolonged QT or severe heart disease;
- 4. Less than 100 days after receiving allogeneic hematopoietic stem cell transplantation;
- 5. Hiv-infected person;
- 6. Persons with active hepatitis B or C virus; Those who are not cured have active infections;
- 7. Insufficient amplification ability (< 5x) in response to CD3 / CD28 costimulatory signals;
- 8. Combined use of systemic steroids (e.g., prednisone ≥20mg) within 3 days prior to screening, except for ongoing or intermittent use of topical, inhaled or intranasal steroids within 2 weeks or at present; Or have systemic diseases that require long-term use of immunological agents;
- 9. Patients who received anti-cancer chemotherapy or other drugs within 2 weeks prior to screening;
- 10. Any situation that the investigator believes may increase the risk of the subjects or interfere with the study results.
Quoted from ClinicalTrials.gov, NCT06793241, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06793241, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.